Cormorant Asset Management
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles.
Business Model:
Revenue: $27.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Cormorant Asset Management Information
Geographic Data
Address:
City: Chagrin Falls
State: OH
Zip: 44022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$253M
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace. Cormorant Asset Management was founded in 2013 and is based in Boston, Massachusetts, United States.
Contact Phone:
+14402473200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2020 | Bigfoot Biomedical | Series C | 0 |
| 2/2022 | Arkuda Therapeutics | Series B | 0 |
| 7/2020 | New Horizon Health | Series E | 30M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 8/2022 | Atia Vision | Series E | 0 |
| 3/2020 | Supira Medical | Series B | 0 |
| 6/2021 | Myra Vision | Series A | 17M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 1/2016 | C4 Therapeutics | Series A | 73M |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 8/2018 | Renovia | Series B | 32.3M |
| 7/2017 | Axonics Modulation Technologies | Series C | 20.5M |
| 3/2021 | Neurelis | Series D | 0 |
| 10/2020 | Olema Oncology | Series C | 85M |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 3/2016 | Quanterix | Series D | 46M |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 12/2019 | FORMA Therapeutics | Series D | 100M |
| 2/2022 | Supira Medical | Series C | 0 |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 5/2019 | Atia Vision | Series D | 0 |
| 10/2016 | Bigfoot Biomedical | Series A | 0 |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 4/2023 | BioVentrix | Series A | 0 |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 4/2022 | MoonLake Immunotherapeutics | Post-IPO Equity | 115M |
| 2/2022 | Greenlight Biosciences | Post-IPO Equity | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 5/2021 | BiVACOR | Series B | 19M |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 1/2021 | FogPharma | Series C | 107M |
| 5/2017 | Axonics Modulation Technologies | Series C | 0 |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 6/2015 | Ardelyx | Post-IPO Equity | 77.8M |
| 3/2021 | EpimAb Biotherapeutics | Series C | 0 |
| 9/2017 | Replimune Group | Series B | 55M |
| 4/2020 | Erasca | Series B | 0 |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 1/2018 | Scholar Rock | Series C | 47M |
| 9/2018 | Atreca | Series C | 125M |
| 8/2017 | Atreca | Series B | 35M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 6/2021 | Myra Vision | Series A | 17M |
| 11/2020 | Pharvaris | Series C | 80M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 3/2021 | Chemomab | Post-IPO Equity | 45.5M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 7/2020 | Olema Oncology | Series B | 54M |
| 2/2016 | Apellis Pharmaceuticals | Series D | 47M |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 5/2017 | Turning Point Therapeutics | Series C | 45M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 9/2020 | Novellus | Series C | 57M |
| 10/2022 | Orionis Biosciences | Series C | 55M |
| 8/2020 | Freenome | Series C | 270M |
| 3/2018 | Bigfoot Biomedical | Series B | 0 |
| 6/2021 | Umoja Biopharma | Series B | 0 |
| 2/2020 | ALX Oncology | Series C | 105M |
| 7/2021 | Tioga Medical | Series B | 0 |
| 12/2015 | X4 Pharmaceuticals | Series A | 37.5M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 12/2018 | Atia Vision | Series C | 10M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 11/2017 | Tricida | Series D | 0 |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 3/2017 | Dicerna Pharmaceuticals | Post-IPO Debt | 0 |
| 2/2018 | Avrobio | Series B | 60M |
| 6/2018 | Cibus | Series C | 70M |
| 11/2020 | Ambrx | Private Equity Round | 200M |
| 4/2018 | Supira Medical | Series A | 15.5M |
| 12/2018 | Erasca | Series A | 42M |
| 11/2021 | Chroma Medicine | Series A | 125M |
| 6/2015 | Kezar Life Sciences | Series A | 23M |
| 3/2020 | Design Therapeutics | Series A | 45.5M |
| 8/2020 | Tango Therapeutics | Venture Round | 50M |
| 9/2020 | Adona Medical | Series A | 0 |
| 4/2022 | Adona Medical | Series B | 0 |
| 5/2020 | Atea | Series D | 215M |
| 10/2021 | ShouTi | Series B | 0 |
| 6/2019 | Viela Bio | Series B | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 1/2016 | Twist Bioscience | Series D | 61M |
| 8/2020 | Aerovate Therapeutics | Series A | 72.6M |
| 2/2018 | Kiniksa Pharmaceuticals | Series C | 200M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 11/2017 | X4 Pharmaceuticals | Series B | 27M |
| 10/2017 | InflaRx | Series D | 55M |
| 9/2020 | Galecto | Series D | 0 |
| 4/2021 | GH Research | Series B | 125M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 10/2020 | Longboard Pharmaceuticals | Series A | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 3/2020 | Element Science | Series C | 145.6M |
| 2/2019 | NuVera Medical | Series B | 15M |
| 2/2019 | Neurogene | Series A | 68.5M |
| 9/2018 | PhaseBio Pharmaceuticals | Series D | 0 |
| 9/2021 | Garuda Therapeutics | Series A | 72M |
| 1/2023 | Ensoma | Series B | 0 |
| 6/2020 | Greenlight Biosciences | Series D | 102M |
| 8/2022 | JenaValve Technology | Series C | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 1/2016 | Scholar Rock | Series B | 36M |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 5/2016 | G1 Therapeutics | Series C | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 4/2021 | Icosavax | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 7/2020 | Praxis Precision Medicines | Series C | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 12/2020 | RayzeBio | Series B | 105M |
| 3/2020 | Akouos | Series B | 105M |
| 6/2021 | Stablix | Series A | 63M |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 8/2022 | Greenlight Biosciences | Post-IPO Equity | 0 |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 4/2018 | Corvidia | Series B | 60M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 3/2016 | ImmuneXcite | Series A | 8.6M |
| 8/2014 | MyoKardia | Venture Round | 0 |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 3/2020 | Pliant Therapeutics | Series C | 0 |
| 12/2017 | Bigfoot Biomedical | Series B | 0 |
| 12/2015 | Axonics Modulation Technologies | Series B | 0 |
| 5/2021 | Elpiscience Biopharmaceuticals | Series C | 0 |
| 2/2023 | Tioga Cardiovascular | Series C | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 7/2021 | Strata Oncology | Series C | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 3/2021 | AgomAb Therapeutics | Series B | 0 |
| 4/2018 | Innovent Biologics | Series E | 150M |
| 3/2021 | DTx Pharma | Series B | 100M |
| 3/2021 | Tyra Biosciences | Series B | 106M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 4/2017 | NuVera Medical | Series A | 11M |
| 10/2021 | Structure Therapeutics | Series B | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 3/2017 | 908 Devices | Series D | 20M |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2017 | Zai Lab | Series C | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 9/2020 | BioShin | Series A | 60M |
| 5/2021 | Jenscare Biotech | Venture Round | - |
| 7/2020 | BioAtla | Series D | 0 |
| 4/2020 | Tango Therapeutics | Series B | 60M |
| 11/2021 | Shoreline Biosciences | Series B | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 6/2016 | Mersana Therapeutics | Series C | 33M |
| 6/2023 | Myra Vision | Series B | 0 |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
| 4/2015 | MyoKardia | Series B | 0 |
| 2/2015 | Advaxis | Post-IPO Equity | 0 |
| 1/2022 | ONK Therapeutics | Series A | 21.5M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 12/2015 | Gelesis | Private Equity Round | 0 |
| 7/2020 | VelosBio | Series B | 137M |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 5/2021 | Numab | Series C | 110.6M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 9/2017 | Autolus | Series C | 80M |
| 1/2022 | Akura Medical | Series A | 25M |
| 8/2015 | Ovid Therapeutics | Series B | 75M |
| 12/2021 | connectRN | Venture Round | 0 |
| 7/2021 | Prime Medicine | Series B | 200M |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 6/2023 | Myra Vision | Series B | 0 |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 4/2023 | BioVentrix | Series A | 0 |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 2/2023 | Tioga Cardiovascular | Series C | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
